AstraZeneca temporarily halted late-stage studies for a COVID-19 vaccine candidate to determine whether the vaccine caused a “potentially unexplained” illness in one of the recipients.
The company said in a statement on the evening of Sept. 8 that its “standard review process triggered a pause to vaccination to allow review of safety data.” The statement did not provide further details. The health news site STAT reported that the pause was prompted by a potential side effect which occurred in the United Kingdom.
